Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... with C5 inhibitor Soliris and

Roche’s Soliris rival satralizumab scores in phase 3 study

Roche’s Soliris rival satralizumab scores in phase 3 study Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen  recently filed a patent infringement action

US, EU regulators start review of Roche’s Soliris rival satralizumab

US, EU regulators start review of Roche’s Soliris rival satralizumab paralysis. At the moment the only approved treatment in the US is Alexion’s complement C5 inhibitor  Soliris (eculizumab), which got a green light from the FDA in June, and there ... Viela thinks inebilizumab has a dosing advantage over both Soliris

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor  Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.

Roche presents new data in NMOSD, could challenge Alexion's Soliris

Roche presents new data in NMOSD, could challenge Alexion's Soliris Reduced risk of relapse by 55%. Roche has presented new data on satralizumab for neuromyelitis optica spectrum disorder (NMOSD),  setting it up for a potential market battle with Alexion’s Soliris. ... progression. Alexion’s Soliris received FDA

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics